Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

BACKGROUND: In the phase III JAVELIN Renal 101 trial, first-line avelumab plus axitinib demonstrated a progression-free survival (PFS) and objective response rate (ORR) benefit versus sunitinib in patients with advanced renal cell carcinoma (aRCC). However, efficacy in elderly patients remains uncle...

Descripción completa

Detalles Bibliográficos
Autores principales: Tomita, Y., Motzer, R.J., Choueiri, T.K., Rini, B.I., Miyake, H., Uemura, H., Albiges, L., Fujii, Y., Umeyama, Y., Wang, J., Mariani, M., Schmidinger, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058903/
https://www.ncbi.nlm.nih.gov/pubmed/35397432
http://dx.doi.org/10.1016/j.esmoop.2022.100450

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9058903/
https://www.ncbi.nlm.nih.gov/pubmed/35397432
http://dx.doi.org/10.1016/j.esmoop.2022.100450

Ejemplares similares